Sign In
Buy PYPD
$4.29
-0.0800 (-1.83%)
At Close: Jul 31, 2026
PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update
07:00am, Wednesday, 12'th May 2021
• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery
PolyPid to Participate in Upcoming Investor Conferences
07:30am, Tuesday, 23'rd Feb 2021
PETAH TIKVA, Israel, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlle
Top-line Data Anticipated by Year End 2021
PolyPid's (PYPD) Management on Q4 2020 Results - Earnings Call Transcript
01:43pm, Wednesday, 10'th Feb 2021
PolyPid's (PYPD) Management on Q4 2020 Results - Earnings Call Transcript
PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021
07:30am, Wednesday, 27'th Jan 2021
PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolo
PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program
07:00am, Tuesday, 22'nd Dec 2020
Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemot
PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections
07:00am, Wednesday, 16'th Dec 2020
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021
PolyPid to Host Key Opinion Leader Call Discussing D-PLEX₁₀₀ and the Prevention of Surgical Site Infections
08:00am, Thursday, 03'rd Dec 2020
PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prol
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q3 2020 Results - Earnings Call Transcript
12:33pm, Wednesday, 11'th Nov 2020
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q3 2020 Results - Earnings Call Transcript
PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results
06:30am, Wednesday, 11'th Nov 2020
• Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval
PolyPid to Participate in Three Upcoming Investor Conferences
08:45am, Wednesday, 04'th Nov 2020
PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolo
PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020
07:00am, Wednesday, 28'th Oct 2020
PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolo
